Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Julian V Pentchev und 56 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Indiana University School of Medicine, Indianapolis, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Multifactorial Inheritance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Alzheimer's Association research.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, USA.
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA.
- Center for Statistical Sciences, Brown University, Providence, USA.
- Department of Neurology, Alpert Medical School, Brown University, Providence, USA.
Förderung
- NIH HHS
- NIA NIH HHS
- Alzheimer's Association research
- U.S. Department of Defense
- National Institutes of Health
Zitieren
APA
Pentchev, J. V., Jackson, T., Khan, N., Rosewood, T. J., Huang, Y. N., Nho, K., Saykin, A. J., Eloyan, A., Taurone, A., Thangarajah, M., Riddle, M., Salloway, S., Atri, A., Honig, L. S., Johnson, E. C. B., Turner, R. S., Masdeu, J. C., Foroud, T. M., Clark, D., …, & Longitudinal Early‐Onset Alzheimer's Disease Study Consortium and the Alzheimer's Disease Neuroimaging Initiative (2026). Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71066
Vancouver
Pentchev JV, Jackson T, Khan N, Rosewood TJ, Huang YN, Nho K, et al. Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71066
BibTeX
@article{Pentchev2026,
author = {Pentchev, Julian V and Jackson, Trever and Khan, Naazneen and Rosewood, Thea J and Huang, Yen-Ning and Nho, Kwangsik and Saykin, Andrew J and Eloyan, Ani and Taurone, Alexander and Thangarajah, Maryanne and Riddle, Meghan and Salloway, Steven and Atri, Alireza and Honig, Lawrence S and Johnson, Erik C B and Turner, Raymond Scott and Masdeu, Joseph C and Foroud, Tatiana M and Clark, David and Hammers, Dustin B and Dage, Jeffrey L and Kirby, Kala and Ghetti, Bernardino and Newell, Kathy and Onyike, Chiadi U and Day, Gregory S and Graff-Radford, Neill R and Murray, Melissa E and Jones, David T and Jack, Clifford R and Vemuri, Prashanthi and Touroutoglou, Alexandra and Duara, Ranjan and Grant, Ian and Sha, Sharon and Wingo, Thomas S and Beckett, Laurel A and Rogalski, Emily and Mendez, Mario F and Kramer, Joel and La Joie, Renaud and Blazhenets, Ganna and Grinberg, Lea T and Koeppe, Robert and Wolk, David A and Aisen, Paul and Raman, Rema and Toga, Arthur and Kukull, Walter A and Musiek, Erik and Womack, Kyle B and Carrillo, Maria C and Rabinovici, Gil D and Dickerson, Bradford C and Apostolova, Liana G and Nudelman, Kelly N H and Longitudinal Early‐Onset Alzheimer's Disease Study Consortium and the Alzheimer's Disease Neuroimaging Initiative, Longitudinal Early‐Onset Alzheimer's Disease Study Consortium and the Alzheimer's Disease Neuroimaging Initiative},
title = {Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71066}
}
EUVIMED